UNRESECTABLE UROTHELIAL CARCINOMA
Clinical trials for UNRESECTABLE UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to outsmart resistant bladder cancer
Disease control Recruiting nowThis study tests whether a combination of two drugs (pembrolizumab and sacituzumab govitecan) works better than standard chemotherapy for advanced bladder cancer that no longer responds to immunotherapy. About 320 adults with locally advanced or metastatic urothelial cancer will …
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New drug cocktail shows promise for tough bladder cancer
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—cabozantinib and enfortumab vedotin—in people with advanced bladder cancer that has spread or cannot be removed. The goal is to find the best dose and see if the combo is safe and shrinks tumors. About 32 adults who have alr…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for bladder cancer: maintenance immunotherapy after combo treatment
Disease control Recruiting nowThis study tests whether a maintenance dose of the immunotherapy drug pembrolizumab can help keep advanced bladder cancer from progressing after an initial combination treatment. About 97 adults with untreated metastatic urothelial carcinoma will receive the combo therapy for 18 …
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo aims to outsmart Drug-Resistant bladder cancer
Disease control Recruiting nowThis early-phase trial tests a new drug combination (emavusertib plus pembrolizumab) in 27 adults with advanced bladder cancer that no longer responds to standard immunotherapy. The goal is to find a safe dose and see if the combo can shrink tumors or slow the disease. Participan…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Cancer patients may soon get infusions at home, cutting travel and stress
Symptom relief Recruiting nowThis study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…
Matched conditions: UNRESECTABLE UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 26, 2026 09:03 UTC